Compare · MEDS vs ZSTK
MEDS vs ZSTK
Side-by-side comparison of DataMeds AI Inc. (MEDS) and ZeroStack Corp. (ZSTK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MEDS and ZSTK operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- ZSTK is the larger of the two at $58.5M, about 12.8x MEDS ($4.6M).
- MEDS has been more active in the news (7 items in the past 4 weeks vs 2 for ZSTK).
- MEDS has more recent analyst coverage (1 ratings vs 0 for ZSTK).
- Company
- DataMeds AI Inc.
- ZeroStack Corp.
- Price
- -
- -
- Market cap
- $4.6M
- $58.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 7
- 2
- Recent ratings
- 1
- 0
DataMeds AI Inc.
DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA -based commercial clinical molecular diagnostics laboratory focused on the ChemoFx Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions.
Latest MEDS
- DataMEDS AI Signs MOU to Deploy Health Lives Here GLP-1 Patient Management Program with Florida-Based HMO
- DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
- DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
- DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
- Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License
- DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
- DataMeds Regains Compliance With NASDAQ Listing Standards
- DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
- DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
- DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
Latest ZSTK
- ZeroStack Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- ZeroStack Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
- SEC Form EFFECT filed by ZeroStack Corp.
- SEC Form AW filed by ZeroStack Corp.
- SEC Form EFFECT filed by ZeroStack Corp.
- SEC Form EFFECT filed by ZeroStack Corp.
- SEC Form EFFECT filed by ZeroStack Corp.
- SEC Form EFFECT filed by ZeroStack Corp.
- SEC Form D filed by ZeroStack Corp.
- SEC Form POS AM filed by ZeroStack Corp.